267875-55-8

Usage

Uses

1H-Indazole-5-carbonitrile, 3-methylis used as a chemical intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique molecular structure allows it to serve as a building block for the development of new drugs and other chemical products.
Used in Pharmaceutical Industry:
1H-Indazole-5-carbonitrile, 3-methylis used as a key intermediate for the synthesis of indazole-based drugs, which have potential applications in the treatment of various diseases. Its presence in the molecular structure of these drugs can influence their pharmacological properties, such as potency, selectivity, and bioavailability.
Used in Agrochemical Industry:
1H-Indazole-5-carbonitrile, 3-methylis used as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can contribute to their effectiveness in controlling pests and weeds, thereby enhancing crop yields and protecting agricultural resources.

Upstream product

• 170230-87-2 4'-amino-3'-ethylbenzonitrile 
• 552331-49-4 tert-butyl 5-bromo-3-methyl-1H-indazole-1-carboxylate 
• 557-21-1 dicyanozinc 
• 552331-16-5 5-bromo-3-methyl-1H-indazole 
• 557-21-1 zinc(II) cyanide 

Downstream Products

• 1015068-76-4 3-methyl-1H-indazole-5-carboxylic acid methyl ester 
• 1015070-98-0 C₁₁H₁₂N₂O₂ 

Relevant academic research and scientific papers

EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF

A 4-substituted-2-(N-(5-substituted allyl amide)phenyl)amino)pyrimidine derivative as represented by formula (I), and a preparation and application thereof as an EGFR inhibitor. The compound has activity of inhibiting the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, may be used to treat diseases mediated alone or in part by EGFR mutant activity, and has a wide application in drugs preventing and treating cancers, particularly non-small cell lung cancer.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.